RCUS: Arcus Biosciences, Inc.
Performance
RCUS -1.86%
Watchlist
Select an item
Summary
RCUS at a glance
RCUS returned -1.86% over the past year and -11.47% a year over five years. Its worst drop in that year was -43.97%, smaller than 31% of stocks on Redstone, and its Sharpe ratio of 0.23 beats 37% of stocks on Redstone. It pays no dividends.
Current Drawdown
-39.97%
Rolling Volatility
89.70%
Actions
Metrics
Risk Indicators
Alpha-0.88%
Beta1.52x
Sharpe0.23
Sortino0.31
Omega1.04
Calmar-0.04
Martin0.85
Profile
About RCUS
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $2.4B
- Listed
- Mar 2018
- Employees
- 601
- Headquarters
- Hayward, CA
- Website
- arcusbio.com
Comparisons